Based on the currently available scientific evidence, HIPEC should not be considered a standard therapeutic option after optimal cytoreduction in advanced ovarian cancer, nor should it be offered outside of a clinical trial.
Maryann Kwa, MD
Advertisement
Articles by Maryann Kwa, MD
Advertisement
Latest Updated Articles
- Clinical Trials of Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Unanswered Questions
Published: September 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Revumenib in R/R NPM1-Mutant AML
2
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
3
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
